The regulatory history of Anapharm, which, besides the GLP and ANVISA certifications, includes 14 studies inspected by FDA and another 12 study specific inspections conducted by European authorities, will certainly enable Anapharm Bioanalytics to strengthen its commercial presence throughout Europe and North America and continue to help its customers achieve their registration goals.

“This is the result of the continuous efforts of Anapharm’s team to ensure day after day the highest scientific and quality standards in the work that we do” stated Anapharm’s Director of Business Development, Robert Fontarnau.

About Anapharm Bioanalytics

30+ years’ experience in LC-MS/Bioanalysis and 15+ years’ experience in LBA assays for antibodies and biomarkers, acknowledges Anapharm Bioanalytics as a world class provider of bioanalytical services to international Sponsors with its strategically located, GLP-certified and GCP-compliant laboratory in Barcelona.

With a successful regulatory history, having undergone 20 successful inspections from health agencies, including FDA (14 studies), GCP inspections from Austria, Italy and Spain (12 studies), as well as GLP certifications by EU authorities and ANVISA (Brazil), Anapharm has become a reliable analytical partner to support its clients at any stage of drug development from preclinical throughout all clinical stages Phase I-IV.

For further details about Anapharm Bioanalytics, please visit our website or contact your Business Development representative at +34 93 223 8636.

With Kind Regards, 

Your Anapharm Team